TY - JOUR
T1 - Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the enhanced suppression of the platelet IIb/IIIa receptor with integrilin therapy [ESPRIT] trial)
AU - Labinaz, Marino
AU - Madan, Mina
AU - O'Shea, J. Conor
AU - Kilaru, Rakhi
AU - Chin, Wai
AU - Pieper, Karen
AU - McGuire, Darren K
AU - Saucedo, Jorge F.
AU - Talley, J. David
AU - Lui, Henry
AU - Kitt, Michael M.
AU - Califf, Robert M.
AU - Tcheng, James E.
N1 - Funding Information:
This study was supported by a grant from COR Therapeutics, South San Francisco, California; and Schering-Plough Corporation, Kenliworth, New Jersey.
PY - 2002
Y1 - 2002
N2 - For patients undergoing nonurgent coronary stent implantation, blockade of the glycoprotein IIb/IIIa receptor with eptifibatide reduces the incidence of ischemic complications. We evaluated the interaction of eptifibatide with diabetes in patients who underwent this procedure by analyzing the 1-year outcomes of those enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial (466 diabetic and 1, 595 nondiabetic patients). At 1 year, the composite end point of death, myocardial infarction (MI), or target vessel revascuarlization (TVR) was higher in diabetic patients (24.5% vs 18.4%; p = 0.008). At 1 year, eptifibatide had a similar effect on the composite end point of death, MI, or TVR in diabetic (hazards ratio [HR] 0.71, 95% confidence interval [CI] 0.49 to 1.04) and nondiabetic patients (HR 0.80, 95% CI 0.63 to 0.99). A similar treatment effect was also seen on death or MI in both groups. The 1-year mortality rate for diabetic patients assigned to placebo was 3.5% versus 1.3% for patients receiving eptifibatide (HR 0.37, 95% CI 0.10 to 1.41); the latter rate was similar to the mortality rate of 1.4% for nondiabetic patients in the eptifibatide group. However, eptifibatide did not have a significant effect on TVR in diabetic patients (HR 0.90, 95% CI 0.57 to 1.41). Our data suggest that treatment with eptifibatide is associated with a similar relative reduction in adverse ischemic complications in diabetic and nondiabetic patients undergoing coronary stent implantation. There is no evidence of a statistical interaction in the treatment effect of eptifibatide between patients with and without diabetes.
AB - For patients undergoing nonurgent coronary stent implantation, blockade of the glycoprotein IIb/IIIa receptor with eptifibatide reduces the incidence of ischemic complications. We evaluated the interaction of eptifibatide with diabetes in patients who underwent this procedure by analyzing the 1-year outcomes of those enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial (466 diabetic and 1, 595 nondiabetic patients). At 1 year, the composite end point of death, myocardial infarction (MI), or target vessel revascuarlization (TVR) was higher in diabetic patients (24.5% vs 18.4%; p = 0.008). At 1 year, eptifibatide had a similar effect on the composite end point of death, MI, or TVR in diabetic (hazards ratio [HR] 0.71, 95% confidence interval [CI] 0.49 to 1.04) and nondiabetic patients (HR 0.80, 95% CI 0.63 to 0.99). A similar treatment effect was also seen on death or MI in both groups. The 1-year mortality rate for diabetic patients assigned to placebo was 3.5% versus 1.3% for patients receiving eptifibatide (HR 0.37, 95% CI 0.10 to 1.41); the latter rate was similar to the mortality rate of 1.4% for nondiabetic patients in the eptifibatide group. However, eptifibatide did not have a significant effect on TVR in diabetic patients (HR 0.90, 95% CI 0.57 to 1.41). Our data suggest that treatment with eptifibatide is associated with a similar relative reduction in adverse ischemic complications in diabetic and nondiabetic patients undergoing coronary stent implantation. There is no evidence of a statistical interaction in the treatment effect of eptifibatide between patients with and without diabetes.
UR - http://www.scopus.com/inward/record.url?scp=0037106945&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037106945&partnerID=8YFLogxK
U2 - 10.1016/S0002-9149(02)02560-2
DO - 10.1016/S0002-9149(02)02560-2
M3 - Article
C2 - 12231081
AN - SCOPUS:0037106945
SN - 0002-9149
VL - 90
SP - 585
EP - 590
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 6
M1 - 10047
ER -